Myricx Pharma Ltd. (d/b/a Myricx Bio)

https://www.myricxbio.com

LinkedIn: https://www.linkedin.com/company/myricx-pharma-ltd

Myricx Bio (“Myricx”) is a UK biotech company focused on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), based on inhibitors of N-Myristoyltransferases (NMT) for the treatment of cancer. NMT is an enzyme that adds a specific lipid modification to a number of protein targets that are key to cancer cell survival. Myricx is advancing a pipeline of ADCs to address serious unmet needs in oncology based on its NMT inhibitor (NMTi) payload chemistry platform and has demonstrated excellent preclinical efficacy and safety across multiple solid tumour-associated antigens and cancer cell types. Based in London, Myricx is a spin out from Imperial College London and the Francis Crick Institute with investment from Abingworth, Brandon Capital Partners, British Patient Capital, Cancer Research Horizons, Eli Lilly and Company, Novo Holdings, and Sofinnova Partners. *

	Start	2019-07-03 established (s-off)
	Predecessor	Imperial College London
	Industry	NMT inhibitor (N-myristoyltransferase inhibitor)
	Industry 2	drug development
	Person	Solari, Roberto (Myricx Pharma 202011 CEO + Co-Founder + Visiting Prof at Imperial College London before GSK)
	Person 2	Hawthorne, Grant (Auspherix 201506– COO)

	Region	London, Greater London
	Country	United Kingdom (GB)
	Street	1 Pancras Square Gridiron Building, King’s Cross
	City	N1C 4AG London
		Address record changed: 2024-06-08

Basic data	Employees	n. a.

		* Document for »About Section«: Myricx Pharma Ltd.. (7/8/24). "Press Release: Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development". London.

		Record changed: 2024-07-15